The stock is already down about 15% in 2023 as the pharmaceutical giant gets set to report earnings.
If the reopening was that bullish shouldn't buyers be more aggressive?
Entering 2023, we can feel inflation easing and are watching for long-term gain from the removal of zero-Covid in China, even if it results in short-term pain.
Funny how re-openings work after forced shutdowns fail in one way or another.
We expect Chinese travelers to return in large numbers, as Asian nations slap new restrictions on arrivals from the last major nation to learn to "live with Covid."
Since 1950, the traditional 'Santa Claus rally' period has produced positive results about 78% of the time.
Let's see how willing buyers are to embrace the hope of a Santa rally.
Private data will need to give us a picture of what's going on in China, where a bleak winter awaits.
Many businesses in China report difficulties due to staffing shortages, but the official tallies of infections and deaths don't reflect that situation.
If the CPI number prints a bit frosty, there will be and should be some questions.